Literature DB >> 4307457

Stimulation and suppression of aldosterone in plasma of normal man and in primary aldosteronism.

R Horton.   

Abstract

The effect of stimulating and suppressive influences on plasma aldosterone in normal man and in patients with primary aldosteronism were studied using a sensitive double-isotope derivative assay for aldosterone. In normal sitting subjects, values were 9.2+/-0.9 (SE) mmug/100 ml and in subjects supine for 1 hr plasma aldosterone was 5.2+/-0.4 (SE) mmug/100 ml. Adrenocorticotropic hormone (ACTH), 0.5 U/hr, produced a rise of 46.8+/-22 (SE) mmug which was similar to the 1-hr effect of an infusion of a synthetic ACTH (beta(1-24), Cortrosyn). Angiotensin II in pressor amounts also increased plasma aldosterone 21.5+/-2.9 (SE) without change in plasma cortisol, whereas a subpressor dose ([unk]) had minimal effect.Fludrocortisone, 1.2 mg/day for 3 days, suppressed plasma aldosterone levels to 1.8+/-0.7 (SE) mmug/100 ml in five normal sitting subjects (P < 0.01); however, dexamethasone, 2 mg/day for 1-2 days, did not lower aldosterone concentration in plasma. In six patients with primary aldosteronism, plasma aldosterone on a normal sodium diet was 39.1+/-4.4 (SE) which differed significantly from normal sitting or supine subjects (P < 0.001). In contrast to the normal subjects, neither a pressor infusion of angiotensin II for 1 hr, nor fludrocortisone, 1.2 mg/day for 3 days, impressively altered plasma aldosterone levels. This approach appears to be useful for the study of the acute physiology and control mechanisms of aldosterone production in normal and hypertensive man.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 4307457      PMCID: PMC322344          DOI: 10.1172/JCI106087

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

Review 1.  REVIEW: THE USE OF ISOTOPIC STEROIDS FOR THE MEASUREMENT OF PRODUCTION RATES IN VIVO.

Authors:  J F TAIT
Journal:  J Clin Endocrinol Metab       Date:  1963-12       Impact factor: 5.958

2.  SUPPRESSION OF PLASMA RENIN ACTIVITY IN PRIMARY ALDOSTERONISM.

Authors:  J W CONN; E L COHEN; D R ROVNER
Journal:  JAMA       Date:  1964-10-19       Impact factor: 56.272

3.  Hypotensive agents and pressor substances. The effect of epinephrine, norepinephrine, angiotensin II, and others on the secretory rate of aldosterone in man.

Authors:  J H LARAGH; M ANGERS; W G KELLY; S LIEBERMAN
Journal:  JAMA       Date:  1960-09-17       Impact factor: 56.272

4.  Double isotope derivative assay of aldosterone in biological extracts.

Authors:  B KLIMAN; R E PETERSON
Journal:  J Biol Chem       Date:  1960-06       Impact factor: 5.157

5.  THE EFFECTS OF INTRAVENOUS INFUSIONS OF VALINE-5 ANGIOTENSIN II AND OTHER PRESSOR AGENTS ON URINARY ELECTROLYTES AND CORTICOSTEROIDS, INCLUDING ALDOSTERONE.

Authors:  P Biron; E Koiw; W Nowaczynski; J Brouillet; J Genest
Journal:  J Clin Invest       Date:  1961-02       Impact factor: 14.808

6.  Control of aldosterone secretion by the pituitary gland.

Authors:  W P Palmore; P J Mulrow
Journal:  Science       Date:  1967-12-15       Impact factor: 47.728

Review 7.  Mechanisms regulating adrenocortical secretion of aldosterone and glucocorticoids.

Authors:  W F Ganong; E G Biglieri; P J Mulrow
Journal:  Recent Prog Horm Res       Date:  1966

8.  Measurement of aldosterone in peripheral blood of man and sheep.

Authors:  J P Coghlan; B A Scoggins
Journal:  J Clin Endocrinol Metab       Date:  1967-10       Impact factor: 5.958

9.  Effect of angiotensin and of frusemide on plasma aldosterone, corticosterone, cortisol and renin in man.

Authors:  R Fraser; V H James; J J Brown; P Isaac; A F Lever; J I Robertson
Journal:  Lancet       Date:  1965-11-13       Impact factor: 79.321

10.  Hypogonadism and mineralocorticoid excess. The 17-hydroxylase deficiency syndrome.

Authors:  O Goldsmith; D H Solomon; R Horton
Journal:  N Engl J Med       Date:  1967-09-28       Impact factor: 91.245

View more
  13 in total

1.  Control of plasma aldosterone in a patient with Conn's syndrome before and during spironolactone medication.

Authors:  H Vetter; W Vetter
Journal:  Klin Wochenschr       Date:  1975-04-15

2.  Specific action of the lipoxygenase pathway in mediating angiotensin II-induced aldosterone synthesis in isolated adrenal glomerulosa cells.

Authors:  J L Nadler; R Natarajan; N Stern
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

3.  Bioassay of aldosterone antagonists in normal human subjects: a relationship between the level of plasma uric acid before treatment and apparent drug responses.

Authors:  L E Ramsay; P Hessian; M J Tidd
Journal:  Br J Clin Pharmacol       Date:  1975-06       Impact factor: 4.335

4.  Site of stimulation of aldosterone biosynthesis by angiotensin and potassium.

Authors:  R D Brown; C A Strott; G W Liddle
Journal:  J Clin Invest       Date:  1972-06       Impact factor: 14.808

5.  Activity of [des-aspartyl1]-angiotensin II in primary aldosteronism.

Authors:  R M Carey; C R Ayers; E D Vaughan; M J Peach; S M Herf
Journal:  J Clin Invest       Date:  1979-04       Impact factor: 14.808

6.  Clinical and biochemical features of patients with aldosterone-producing adenoma and idiopathic hyperaldosteronism.

Authors:  H Witzgall; O A Müller; P C Weber
Journal:  Klin Wochenschr       Date:  1983-01-03

7.  [Diurnal profiles of plasma aldosterone, cortisol, renin, angiotensinogen and angiotensinases in normal subjects (author's transl)].

Authors:  D Lommer; A Distler; H P Nast; K Sinterhauf; U Walter; H P Wolff; K Sieler
Journal:  Klin Wochenschr       Date:  1976-02-01

8.  Periodic hypokalaemic paralysis, adrenal adenoma, and normal colonic transport of sodium and potassium.

Authors:  P Richards; M B Jones; W S Peart
Journal:  Gut       Date:  1973-06       Impact factor: 23.059

9.  Plasma aldosterone concentration at delivery and during the newborn period.

Authors:  I Z Beitins; F Bayard; L Levitsky; I G Ances; A Kowarski; C J Migeon
Journal:  J Clin Invest       Date:  1972-02       Impact factor: 14.808

10.  Circadian rhythm of plasma aldosterone concentration in patients with primary aldosteronism.

Authors:  D C Kem; M H Weinberger; C Gomez-Sanchez; N J Kramer; R Lerman; S Furuyama; C A Nugent
Journal:  J Clin Invest       Date:  1973-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.